Literature DB >> 32097710

CRISPR system: Discovery, development and off-target detection.

Shengmiao Chen1, Yufeng Yao1, Yanchun Zhang1, Gaofeng Fan2.   

Abstract

As a revolutionary gene editing tool based on the adaptive immune defense mechanism of bacteria and archaea against exogenous DNA invasion, CRISPR/Cas system shows many remarkable characteristics over ZFNs and TALENs. However, off-target effect remains as one of the major imperfection of CRISPR/Cas system, hindering its further application in translational research. In this review, we highlight major breakthrough cross the development/application of this powerful toolkit, and summarize feasible methods for detecting potential off-target effects during genetic manipulation. We hope this review will assist scientists for accurate genomic editing in their future research.
Copyright © 2020 Elsevier Inc. All rights reserved.

Keywords:  CRISPR; Cas9; Genome editing; Off-target

Mesh：

Substances：

Year:  2020        PMID： 32097710     DOI： 10.1016/j.cellsig.2020.109577

Source DB:  PubMed          Journal:  Cell Signal        ISSN： 0898-6568            Impact factor:   4.315


  10 in total

Review 1.  "Genetic scissors" CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair.

Authors:  Chao Li; Yawei Du; Tongtong Zhang; Haoran Wang; Zhiyong Hou; Yingze Zhang; Wenguo Cui; Wei Chen
Journal:  Bioact Mater       Date:  2022-10-07

Review 2.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 3.  Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges.

Authors:  Misganaw Asmamaw Mengstie
Journal:  Front Bioeng Biotechnol       Date:  2022-05-12

Review 4.  Evolving AAV-delivered therapeutics towards ultimate cures.

Authors:  Xiangjun He; Brian Anugerah Urip; Zhenjie Zhang; Chun Christopher Ngan; Bo Feng
Journal:  J Mol Med (Berl)       Date:  2021-02-16       Impact factor: 4.599

Review 5.  Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system.

Authors:  Yuquan Zhang; Ziyue Li; Julien Milon Essola; Kun Ge; Xuyan Dai; Huining He; Haihua Xiao; Yuhua Weng; Yuanyu Huang
Journal:  Biosaf Health       Date:  2022-03-14

6.  Ribozyme-mediated CRISPR/Cas9 gene editing in pyrethrum (Tanacetum cinerariifolium) hairy roots using a RNA polymerase II-dependent promoter.

Authors:  Jia-Wen Li; Tuo Zeng; Zhi-Zhuo Xu; Jin-Jin Li; Hao Hu; Qin Yu; Li Zhou; Ri-Ru Zheng; Jing Luo; Cai-Yun Wang
Journal:  Plant Methods       Date:  2022-03-16       Impact factor: 4.993

Review 7.  Recent Advances in Improving Gene-Editing Specificity through CRISPR-Cas9 Nuclease Engineering.

Authors:  Xiaoqiang Huang; Dongshan Yang; Jifeng Zhang; Jie Xu; Y Eugene Chen
Journal:  Cells       Date:  2022-07-13       Impact factor: 7.666

8.  PERM1 regulates genes involved in fatty acid metabolism in the heart by interacting with PPARα and PGC-1α.

Authors:  Chun-Yang Huang; Shin-Ichi Oka; Xiaoyong Xu; Chian-Feng Chen; Chien-Yi Tung; Ya-Yuan Chang; Youssef Mourad; Omair Vehra; Andreas Ivessa; Ghassan Yehia; Peter Romanienko; Chiao-Po Hsu; Junichi Sadoshima
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

Review 9.  Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.

Authors:  Giulia Paolini Sguazzi; Valentina Muto; Marco Tartaglia; Enrico Bertini; Claudia Compagnucci
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

Review 10.  CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer.

Authors:  Sushmaa Chandralekha Selvakumar; K Auxzilia Preethi; Kehinde Ross; Deusdedit Tusubira; Mohd Wajid Ali Khan; Panagal Mani; Tentu Nageswara Rao; Durairaj Sekar
Journal:  Mol Cancer       Date:  2022-03-24       Impact factor: 27.401
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.